Saniona announces that FDA has approved the IND for NS2359 in cocaine addiction

Saniona, a leading biotech company within ion-channel research, announces today that the US Food and Drug Administration, FDA, has accepted the University of Pennsylvania Treatment Research Center's (TRC) Investigational New Drug Application (IND) for NS2359. TRC is currently applying for public funding with the aim of conducting a Phase 2 clinical trial for NS2359 for treatment of cocaine addiction.

The release as fetched from its publisher. saniona.com ↗